Oncotarget

Research Papers:

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia

Ban Xiong Tan, Kian Hoe Khoo, Tit Meng Lim and David Philip Lane _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:933-943. https://doi.org/10.18632/oncotarget.1559

Metrics: PDF 2857 views  |   HTML 3007 views  |   ?  


Abstract

Ban Xiong Tan1, Kian Hoe Khoo1, Tit Meng Lim2, David Philip Lane1

1 p53 Laboratory, A-STAR, Singapore

2 Department of Biological Sciences, National University of Singapore, Singapore

Correspondence:

David P. Lane, email:

Keywords: p53, AML, Mdm4

Received: October 31, 2013 Accepted: November 20, 2013 Published: November 22, 2013

Abstract

Although p53 is found mutated in almost 50% of all cancers, p53 mutations in leukaemia are relatively rare. Acute myeloid leukaemia (AML) cells employ other strategies to inactivate their wild type p53 (WTp53), like the overexpression of the p53 negative regulators Mdm2 and Mdm4. As such, AMLs are excellent candidates for therapeutics involving the reactivation of their WTp53 to restrict and destroy cancer cells, and the Mdm2 antagonist nutlin-3 is one such promising agent. Using AML cell lines with WTp53, we identified stable and high levels of p53 in the OCI/AML-2 cell lines. We demonstrate that this nutlin-3 sensitive cell line overexpressed Mdm4 to sequester, stabilise and inhibit p53 in the cytoplasm. We also show that elevated Mdm4 competed with Mdm2-p53 interaction and therefore extended p53 half-life while preventing p53 transcriptional activity. Our results provide biochemical evidence on the dynamics of the p53-Mdm2-Mdm4 interactions in affecting p53 levels and activity, and unlike previously reported findings derived from genetically manipulated systems, AML cells with naturally high levels of Mdm4 remain sensitive to nutlin treatment.

Key Points

Endogenously high levels of Mdm4 inhibit and sequester p53 in AML.

High levels of Mdm4 do not block function of Mdm2 inhibitors in AML.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1559